Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | F2RL3 | Q96RI0 | 8/20 | 0.39 |
| ▸ | CCNK | O75909 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PI4KA | P42356 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1945189 | 0.88 | FYN (0.68) | FYNALDH1A1GAAF2RL3CCNK | |
| SCHEMBL1947142 | 0.83 | FYN (0.68) | FYNF2RL3CCNKCDK9 | |
| SCHEMBL1946744 | 0.83 | FYN (0.56) | FYNALDH1A1F2RL3 | |
| SCHEMBL1945145 | 0.82 | FYN (0.47) | FYNF2RL3CCNKCDK9PIK3CD | |
| SCHEMBL1651226 | 0.82 | IDO1 (0.45) | FYNALDH1A1GAAMAPK1PI4KB | |
| SCHEMBL1946052 | 0.82 | FYN (0.53) | FYNF2RL3PIK3CDPI4KAPIK3CG | |
| SCHEMBL1946366 | 0.81 | FYN (0.53) | FYNF2RL3CCNKCDK9 | |
| SCHEMBL1946231 | 0.80 | FYN (0.58) | FYNALDH1A1GAAF2RL3 | |
| SCHEMBL1944660 | 0.80 | FYN (0.46) | FYNF2RL3CCNKCDK9PIK3CD | |
| SCHEMBL1945560 | 0.80 | MAPT (0.49) | FYNF2RL3CCNKCDK9PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307425-B1 | IMIDAZOTHIADIAZOLES DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-26 | — | — | EP | claimed |
| US-8389554-B2 | Imidazothiadiazole derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-03-05 | — | — | US | claimed |
| JP-2011529456-A | — | — | 2011-12-08 | — | — | JP | claimed |
| US-20110130396-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-06-02 | — | — | US | claimed |
| EP-2307425-A1 | IMIDAZOTHIADIAZOLES DERIVATIVES | Merck Patent GmbH (DE) | 2011-04-13 | — | — | EP | claimed |
| WO-2010012345-A1 | IMIDAZOTHIADIAZOLES DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-02-04 | — | — | WO | claimed |
| EP-2307425-B1 | IMIDAZOTHIADIAZOLES DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-26 | — | — | EP | disclosed |
| US-8389554-B2 | Imidazothiadiazole derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-03-05 | — | — | US | disclosed |
| US-20110130396-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-06-02 | — | — | US | disclosed |
| EP-2307425-A1 | IMIDAZOTHIADIAZOLES DERIVATIVES | Merck Patent GmbH (DE) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010012345-A1 | IMIDAZOTHIADIAZOLES DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130396-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES | TGFBR1, TGFBR2, IGF1R | FYN 1977/4885ALDH1A1 416/4885GAA 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.